Skip to content

Fractional laser as treatment option for various pigment disorders

Fractional laser as treatment option for various pigment disorders - Fractionallaserinpigmentdisorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON33568
Enrollment
60
Registered
2009-02-06
Start date
2009-02-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pigment disorders spotted disease

Interventions

fractional laser therapy every 3-6 weeks with a maximum of 5 treatments dependant on skin type and disorder

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Melasma and postinflammatory hyperpigmentation : skin photo type I-V ; Becker naevus: skin photo type I-III ; Ochronosis and ashy dermatosis : skin photo type IV-V ; resistant Ota naevus: skin photo type III-IV ; Subjects attending the outpatient department of the Netherlands Institute for Pigment Disorders; Age at least 18 years; Subject is willing and able to give written informed consent.

Exclusion criteria

Exclusion criteria: Bleaching cream during the past 6 weeks; Local corticosteroids during the past 6 weeks; Subjects with a history of keloid; Subjects with active eczema; Subjects with active acne in the face; Subjects with a history of facial eczema; Suspect allergy to lidocaine or triple therapy; Use of roaccutane in the past 6 months; Subjects not competent to understand what is involved; Pregnancy; Lesion suspicious for malignancy; High exposure to sunlight (vacation in southern countries) or UV light (UVA or UVB).

Design outcomes

Primary

MeasureTime frame
Objective colour measurements by physician*s global assessment (PhGA), reflectance spectroscopy, clinical melasma score (MASI), patient*s satisfaction, patient*s global assessment (PGA), and visual assessment of side effects.

Secondary

MeasureTime frame
-

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)